Have you been diagnosed with atrial fibrillation
by your doctor but are not currently taking
a blood thinner (or “anticoagulant”)?

Is the LILAC – TIMI 76 study right for you?

Patients diagnosed with atrial fibrillation who might be well-suited for this trial include
those who:

• Are age 65 years or older
• Have factors that increase risk of stroke and bleeding
• Have liver or kidney issues
• Are taking multiple medications
• Are not appropriate for currently available blood thinners (as determined by a doctor)

If you have atrial fibrillation but have never taken a blood thinner, or stopped taking your blood thinner more than 60 days ago, you may be eligible to participate

Discuss the LILAC – TIMI 76 trial with your doctor

Medical experts recommend anticoagulants (also called “blood thinners”) for patients with atrial fibrillation

In patients who have atrial fibrillation, blood can pool inside the heart, forming blood clots. If a clot breaks loose, it can travel through the bloodstream to the brain and cause a stroke.

Compared with people without atrial fibrillation, patients with atrial fibrillation are:

5 times more likely to have a stroke

More likely to have a severe stroke

Blood thinners help reduce the risk of harmful clotting and stroke, but the risk of bleeding can be a trade-off

When you take a blood thinner, you have a higher risk of bleeding, including serious bleeding, especially after an injury. This happens because blood thinners reduce how much your blood clots, and current medications can reduce both bad and good clotting.

Current blood thinners might not be right for all patients

Patient factors that increase the risk of bleeding might also mean your doctor doesn’t think you
should take a currently available blood thinner

What is different about this clinical trial?

The LILAC – TIMI 76 trial is evaluating a new type of monthly blood thinner

• Blood thinners like rivaroxaban and apixaban are often given to patients with atrial fibrillation, but these medications are associated with a risk of bleeding
• A new generation of blood thinners called Factor XI (Factor Eleven) inhibitors are thought to prevent blood clots without increasing the risk of bleeding
• The blood thinner patients will take in the LILAC – TIMI 76 trial is delivered by a once-monthly injection

To participate in this trial, you must have atrial fibrillation but—because of your doctor’s decision or your preference—you are not taking a blood thinner

• There will be an initial screening period with tests, assessments, and questionnaires to determine if this trial is right for you
• For each participant, the trial is expected to last for about 18 months (1½ years)

Discuss the LILAC – TIMI 76 trial with your doctor to determine whether it might be right for you

Trial site locations across
the US

Select from the letters below to filter states viewed.

References:

1. ClinicalTrials.gov identifier: NCT05712200. Updated August 22, 2024. Accessed September 11, 2024. https://www.clinicaltrials.gov/study/NCT05712200. 2. Camm AJ, et al. Eur Heart J. 2010;31(19):2369-2429. 3. Piccini JP Sr, Fonarow GC. JAMA Cardiol. 2016;1(1):63-64. 4. Joglar JA, et al. J Am Coll Cardiol. 2024;83(1):109-279. 5. Hsu C, et al. J Am Coll Cardiol. 2021;78(6):625-631.